Tags : VAC2

BioTime Acquires Asterias Biotherapeutics with Two of its Clinical Stage

Vartika Singh November 15, 2018

Shots: Asterias to receive 0.71 share, for each of its share in BioTime making it an ownership of 16.2%. Biotime to get hold of all stock of Asterias along with […]readmore

Tags : VAC2

BioTime Acquires Asterias Biotherapeutics with Two of its Clinical Stage

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : VAC2

BioTime Acquires Asterias Biotherapeutics with Two of its Clinical Stage

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company